Takeda signs option agreement with ascentage pharma to enter into exclusive global license for olverembatinib, a third-generation bcr-abl tyrosine kinase inhibitor (tki)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced the signing of an option agreement with ascentage pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation bcr-abl tyrosine kinase inhibitor (tki), which is currently in development for chronic myeloid leukemia (cml) and other hematological cancers. if exercised, the option would allow takeda to license global rights to develop and comm.
TAK Ratings Summary
TAK Quant Ranking